Skip to content
#explainable ai Review Open access

Varenicline as a Repurposable Drug Candidate for ADRD Prevention

Sep 2026 · medRxiv · 0 citations
Medicine

TL;DR

Varenicline use is associated with a lower risk of ADRD among older adults receiving smoking cessation therapy and the value of explainable AI-guided approaches to drug repurposing is underscored.

Abstract

Objective: Effective strategies to prevent Alzheimer's disease and related dementias (ADRD) are limited. Implementing our Medication-Wide Association Study (MWAS+), we highlighted varenicline as a candidate. This study evaluated the association between varenicline use and risk of ADRD relative to nicotine replacement therapy (NRT). Methods: Using the All of Us Research Database, we identified adults aged 50 years or older with available lifestyle survey responses regarding tobacco use history who initiated smoking cessation therapy with either varenicline or NRT between 2006 and 2023. We limited our cohort to incident monotherapy users and designated the index date as the first prescription. Individuals with baseline ADRD or no follow-up were excluded. Baseline characteristics included demographics, comorbidities, BMI, and prior medication exposures. Outcomes were incident ADRD and a composite outcome of ADRD or death. Findings: The cohort consisted of 9,584 individuals (1,801 varenicline users and 7,783 NRT users). After propensity score matching, there were 1,758 individuals in each group with balanced baseline characteristics. Varenicline use was associated with a reduced risk of ADRD (HR 0.516, 95% CI: 0.353-0.754) and the composite outcome ADRD or death (HR 0.657, 95% CI: 0.501-0.861). Kaplan-Meier curves also demonstrated varenicline's sustained benefits through the study period. Implications: Varenicline use is associated with a lower risk of ADRD among older adults receiving smoking cessation therapy. Further investigation of varenicline as a potential strategy for ADRD prevention is warranted. These findings underscored the value of explainable AI-guided approaches to drug repurposing.

Read PDF

Similar papers

Open access Sep 2026

Ursodeoxycholic Acid and Parkinson's Disease Risk: An Emulated Target Trial in UK Electronic Health Records.

BACKGROUND Ursodeoxycholic acid (UDCA) has shown mitochondrial and neuroprotective effects and has been proposed as a treatment for Parkinson's disease (PD). However, population-level evidence on its effect on PD risk is lacking. OBJECTIVES To compare the risk of incident PD among UDCA initiators versus matched non-i...

C. Ju, A. Schrag, Camille B. Carroll et al. · 0 citations
Open access Sep 2026

Association of lithium versus valproate initiation with all-cause mortality and incident dementia: a multinational real-world cohort study

Background Lithium and valproate are widely prescribed mood stabilizers, but their comparative long-term associations with mortality and dementia remain uncertain. We compared the risks of all-cause mortality and incident dementia among adults initiating lithium or valproate using a large multinational electronic healt...

Da-Han Hou, Yu-Hsien Wu, Ming-Ju Wu et al. · 0 citations
Open access Aug 2026

Antidiabetic medications and risk of cognitive disorders in type 2 diabetes: A retrospective cohort study

Objective To evaluate the associations between commonly used antidiabetic regimens and incidence of mild cognitive disorder, Alzheimer disease, and vascular dementia in adults with type 2 diabetes. Design, setting, and participants This retrospective cohort study used the TriNetX US Collaborative Network of electronic...

A. B. Nasir, Yassine Kilani, Mohammad Aldiabat et al. · 0 citations
Sep 2026

Treatment Duration of Cholinesterase Inhibitor Formulations in Alzheimer's Disease.

OBJECTIVES To examine treatment duration of oral and transdermal cholinesterase inhibitor formulations in older adults with severe Alzheimer's disease (AD) in routine clinical practice. DESIGN Retrospective population-based cohort study. SETTING AND PARTICIPANTS Linked medical and long-term care insurance claims da...

So Sato, Y. Sasabuchi, H. Yamana et al. · 0 citations
Meta-analysis Open access Aug 2026

Meta-analysis and pharmacoeconomic study of rasagiline versus selegiline in the treatment of Parkinson’s disease

Abstract Objective Given the persistent absence of direct head-to-head trials, this study aimed to evaluate the comparative efficacy, safety, and cost-effectiveness of rasagiline versus selegiline as early-stage monotherapy for Parkinson’s disease (PD), informing clinical selection and healthcare policies in China. Met...

Hanzong Zhou, Dandan Li, Jun-Xian Yu et al. · 0 citations
Open access Sep 2026

Pharmacological management in frontotemporal dementia and patient outcomes: a retrospective cohort study using the TriNetX platform

Symptomatic treatment remains the cornerstone of therapeutic management in frontotemporal dementia (FTD), as disease-modifying therapies are currently unavailable. However, several medications originally developed for other neuropsychiatric conditions may represent potentially harmful medications (PHMs) in FTD. This st...

L. Botton, F. J. Lazzaretti, Carlos Lokschin et al. · 0 citations

Related blog posts

Microsoft Research Blog Nov 16, 2026

TokenEconomizer: Learning from Experience to Make AI Coding Agents More Efficient

AI coding agents are increasingly help developers fix bugs and build features largely on their own, but every interaction with their models consumes tokens. In each session, an agent sends instructions, tool descriptions, and session history to its model. Most efforts to reduce this cost focus on individual tasks. Yet developers return to the same […] The post TokenEconomizer: Learning from Experience to Make AI Coding Agents More Efficient appeared first on Microsoft Research.

GPT-Lab Nov 13, 2026

TenderIntell at ICSOB 2026: Three Days in Gothenburg

At ICSOB 2026 in Gothenburg, we presented TenderIntell, our work on multi-agent support for tendering. This post looks back at the conference, the idea behind a panel of three AI reviewers who score each proposal independently, and why evaluating agents reliably is the question we keep coming back to. The post TenderIntell at ICSOB 2026: Three Days in Gothenburg appeared first on GPT-Lab.

MIT News · Artificial Intelligence Nov 13, 2026

Helping robots fit into the human workplace

Founded by Anthony Jules ’92, SM ’92 and Professor Emeritus Rodney Brooks, Robust AI’s robots are designed to collaborate with humans in factories and warehouses.

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.